AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian Cancer
AVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.
Immune monitoring showed activation of both CD8+ cytotoxic and CD4+ helper T cells, while regulatory T-cell numbers did not increase, indicating a favorable immune profile.
These findings provide early evidence that AVB-001 can safely engage the immune system in a disease setting with limited options, supporting further clinical development.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that